ITCS20080020A1 - METHOD AND KIT FOR DETERMINING THE CONCENTRATION OF PEROXIDES IN AN ORGANIC LIQUID - Google Patents
METHOD AND KIT FOR DETERMINING THE CONCENTRATION OF PEROXIDES IN AN ORGANIC LIQUIDInfo
- Publication number
- ITCS20080020A1 ITCS20080020A1 IT000020A ITCS20080020A ITCS20080020A1 IT CS20080020 A1 ITCS20080020 A1 IT CS20080020A1 IT 000020 A IT000020 A IT 000020A IT CS20080020 A ITCS20080020 A IT CS20080020A IT CS20080020 A1 ITCS20080020 A1 IT CS20080020A1
- Authority
- IT
- Italy
- Prior art keywords
- solution
- concentration
- organic liquid
- peroxides
- sample
- Prior art date
Links
- 150000002978 peroxides Chemical class 0.000 title claims description 32
- 239000007788 liquid Substances 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 239000012086 standard solution Substances 0.000 claims description 15
- 239000012224 working solution Substances 0.000 claims description 15
- 239000007853 buffer solution Substances 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000012153 distilled water Substances 0.000 claims description 11
- 230000003287 optical effect Effects 0.000 claims description 9
- 239000012488 sample solution Substances 0.000 claims description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 6
- 239000001632 sodium acetate Substances 0.000 claims description 6
- 235000017281 sodium acetate Nutrition 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- ZEMODTUZIWTRPF-UHFFFAOYSA-N 1-n,4-n-diethylbenzene-1,4-diamine Chemical compound CCNC1=CC=C(NCC)C=C1 ZEMODTUZIWTRPF-UHFFFAOYSA-N 0.000 claims description 4
- 239000006193 liquid solution Substances 0.000 claims description 2
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Description
Metodo e Kit per la determinazione della concentrazione di perossidi in un liquido organico Method and Kit for determining the concentration of peroxides in an organic liquid
Campo della tecnica dell’invenzione. Field of the technique of invention.
La presente invenzione riguarda un metodo ed un kit per determinazione della concentrazione di perossidi in un liquido organico, quale per esempio il sangue, la saliva, l’urina ecc. Il kit à ̈ semplice da usare con l’attrezzatura di un normale laboratorio di analisi. The present invention relates to a method and a kit for determining the concentration of peroxides in an organic liquid, such as for example blood, saliva, urine, etc. The kit is simple to use with the equipment of a normal analysis laboratory.
Stato dell’arte State of the art
Il perossido di idrogeno (idroperossido) interviene in molte reazioni metaboliche ossigeno dipendendenti e funge da chiave di regolazione per una serie di processi ossidativi e stati connessi. Hydrogen peroxide (hydroperoxide) is involved in many oxygen-dependent metabolic reactions and acts as a regulatory key for a number of oxidative processes and related states.
Il funzionamento avviene attraverso NF-Kappa B e altri fattori. Operation occurs through NF-Kappa B and other factors.
I percorsi mediati dai perossidi sono stati collegati ad asma, artrite infiammatoria, arteriosclerosi, vasculopatia diabetica, osteoporosi, un certo numero di malattie neuro degenerative e la sindrome di Down. Peroxide-mediated pathways have been linked to asthma, inflammatory arthritis, arteriosclerosis, diabetic vasculopathy, osteoporosis, a number of neuro-degenerative diseases and Down's syndrome.
La determinazione dei perossidi à ̈ anche d’aiuto nella valutazione dei rischi di retinopatia diabetica e di qualche malattia infettiva cronica come l’epatite C, alti valori di perossidi sono stati riscontrati anche nel siero di donne che assumono contraccettivi orali. The determination of peroxides is also helpful in assessing the risks of diabetic retinopathy and some chronic infectious diseases such as hepatitis C, high peroxide values have also been found in the serum of women taking oral contraceptives.
La misurazione dei perossidi può concorrere a determinare il modo in cui lo stress ossidativo contribuisce a modulare svariate vie intracellulari. The measurement of peroxides can help determine how oxidative stress contributes to modulating various intracellular pathways.
Alcuni autori avendo verificato, in recenti studi, che i radicali liberi giocano un ruolo importante negli stati infiammatori nelle malattie post - ischemiche dell’apparato digerente, nelle alterazioni del sistema nervoso centrale risultante da disfunzioni vascolari e traumatiche,arteriosclerosi e complicazioni cardiache, malattie renali, artriti deformanti e reumatoidi, malattie provocate dall’alcohol, propongono di misurare le concentrazioni di radicali liberi. Some authors having verified, in recent studies, that free radicals play an important role in inflammatory states in post-ischemic diseases of the digestive system, in alterations of the central nervous system resulting from vascular and traumatic dysfunctions, atherosclerosis and cardiac complications, kidney, deforming and rheumatoid arthritis, diseases caused by alcohol, propose to measure the concentrations of free radicals.
In particolare US-B-6355489 propone di misurare i radicali liberi, purtroppo però i radicali liberi sono instabili e tendono a sottrarre elettroni ad altre molecole per trovare stabilità , la loro esistenza ha vita breve , dell’ordine di pochi secondi. Di conseguenza, la loro misura à ̈ difficile se non impossibile. In particular US-B-6355489 proposes to measure free radicals, unfortunately, however, free radicals are unstable and tend to steal electrons from other molecules to find stability, their existence is short-lived, of the order of a few seconds. Consequently, their measurement is difficult if not impossible.
Pertanto, il metodo proposto in US-B-6355489 mira a misurare i radicali liberio che sono altamente variabili in tempi molto ristretti. Therefore, the method proposed in US-B-6355489 aims to measure the liberium radicals which are highly variable in a very short time.
La presente invenzione si propone lo scopo di superare gli svantaggi e le difficoltà presenti nei metodi proposti dallo stato dell’arte. The present invention aims to overcome the disadvantages and difficulties present in the methods proposed by the state of the art.
Sommario della presente invenzione Summary of the present invention
La presente invenzione si propone, invece, di misurare la concentrazione di perossidi contenuti in un liquido organico attraverso il riferimento ad una soluzione standard costituita da una soluzione acquosa avente una concentrazione di perossidi pari a 8,9 mgr di H2O2/dl The present invention, on the other hand, aims to measure the concentration of peroxides contained in an organic liquid by referring to a standard solution consisting of an aqueous solution having a peroxide concentration equal to 8.9 mgr of H2O2 / dl
Lo scopo principale della presente invenzione à ̈ conseguito per mezzo di un metodo per la determinazione della concentrazione di perossidi in un liquido organico caratterizzato dal fatto che si prepara una soluzione di lavoro mescolando una soluzione tampone avente pH 4,5 e un cromogeno indiluito, che si prepara una soluzione campione formata da un campione di liquido organico sciolto nella soluzione di lavoro in un rapporto volumetrico definito tra liquido organico e soluzione di lavoro, che viene utilizzata una soluzione standard formata da acqua ossigenata H2O2in acqua distillata, che viene determinata la densità ottica della soluzione campione e della soluzione standard, che la concentrazione di perossidi nel campione di liquido organico à ̈ data dal prodotto della concentrazione di perossidi contenuti nella soluzione standard per il rapporto tra la densità ottica della soluzione campione e di quella della soluzione standard. The main object of the present invention is achieved by means of a method for determining the concentration of peroxides in an organic liquid characterized in that a working solution is prepared by mixing a buffer solution having pH 4.5 and an undiluted chromogen, which a sample solution is prepared consisting of a sample of organic liquid dissolved in the working solution in a defined volumetric ratio between organic liquid and working solution, which is used a standard solution formed by hydrogen peroxide H2O2 in distilled water, which is determined the optical density of the sample solution and of the standard solution, that the concentration of peroxides in the sample of organic liquid is given by the product of the concentration of peroxides contained in the standard solution by the ratio between the optical density of the sample solution and that of the standard solution.
Altra caratteristica à ̈ data dal fatto che la soluzione tampone à ̈ costituita da 136 gr di acetato di sodio e 60 ml di acido acetico in 1.000 ml di acqua distillata. Another feature is given by the fact that the buffer solution consists of 136 g of sodium acetate and 60 ml of acetic acid in 1,000 ml of distilled water.
Altra caratteristica à ̈ data dal fatto che la soluzione di lavoro à ̈ costituita da 1 parte di cromogeno e da 1000 a 6000 parti di soluzione tampone. Another feature is given by the fact that the working solution is made up of 1 part of chromogen and from 1000 to 6000 parts of buffer solution.
Altra caratteristica à ̈ data dal fatto che la soluzione campione à ̈ costituita da liquido organico sciolto nella soluzione di lavoro nel rapporto di 20µl di liquido organico in 1000 µl di soluzione di lavoro e che la soluzione standard, formata da acqua ossigenata H2O2 ,in acqua distillata ha una concentrazione di perossidi pari a 8,9 mgr di H2O2/dl. Another feature is given by the fact that the sample solution consists of organic liquid dissolved in the working solution in the ratio of 20µl of organic liquid in 1000 µl of working solution and that the standard solution, formed by hydrogen peroxide H2O2, in water when distilled it has a peroxide concentration equal to 8.9 mgr of H2O2 / dl.
Altro obbiettivo principale dell’invenzione à ̈ di fornire un Kit per la esecuzione del metodo per la determinazione della concentrazione di perossidi in un liquido organico caratterizzato dal fatto che esso da à ̈ formato da tre reagenti, un reagente A formato dal cromogeno di sintesi indiluito N-N Dietil 1,4 phenilendiamina; da un reagente B formato da una soluzione tampone costituita da 136 gr di acetato di sodio e 60 ml di acido acetico in 1.000 ml di acqua distillata e da un reagente C formato da H2O2, idroperossido, in acqua distillata avente una concentrazione di perossidi pari a 8,9 mgr di H2O2/dl. Another main objective of the invention is to provide a kit for carrying out the method for determining the concentration of peroxides in an organic liquid characterized by the fact that it is formed by three reagents, a reagent A formed by the synthesis chromogen undiluted N-N Diethyl 1,4 phenylenediamine; a reagent B formed by a buffer solution consisting of 136 g of sodium acetate and 60 ml of acetic acid in 1,000 ml of distilled water and a reagent C formed of H2O2, hydroperoxide, in distilled water having a peroxide concentration equal to 8.9 mgr of H2O2 / dl.
Altre caratteristiche e vantaggi dell'invenzione appariranno chiari dalla descrizione di un modo di realizzazione dell’invenzione, qui appresso, dati a titolo d'esempio non limitativo. Other characteristics and advantages of the invention will become clear from the description of a way of carrying out the invention, hereinafter, given by way of non-limiting example.
Modo preferito di realizzazione dell’invenzione Preferred way of carrying out the invention
Un cromogeno di sintesi indiluito N-N Dietil 1,4 phenilendiamina mescolato con una soluzione tampone per formare una soluzione di lavoro. An undiluted synthetic chromogen N-N Diethyl 1,4 phenylenediamine mixed with a buffer solution to form a working solution.
Il cromogeno à ̈ costituito da N-N Dietil 1,4 phenilendiamina di sintesi indiluito. The chromogen is made up of N-N Diethyl 1,4 synthetic undiluted phenylenediamine.
La soluzione tampone à ̈ costituita da 136 gr di acetato di sodio e 60 ml di acido acetico in acqua fino a 1.000 ml, la soluzione tampone ha un pH di circa 4,5. The buffer solution consists of 136 g of sodium acetate and 60 ml of acetic acid in water up to 1,000 ml, the buffer solution has a pH of about 4.5.
Per realizzare la soluzione di lavoro occorrono 1 parte di cromogeno e da 1000 a 6000 parti di soluzione tampone. To make the working solution, 1 part of chromogen and 1000 to 6000 parts of buffer solution are required.
Viene preparata la soluzione standard di H2O2alla concentrazione di 8,9 mgr di H2O2/dl e la soluzione con il campione costituita da 20µl di campione in 1000 µl di soluzione di lavoro. The standard solution of H2O2 is prepared at a concentration of 8.9 mgr of H2O2 / dl and the solution with the sample consisting of 20µl of sample in 1000 µl of working solution.
Viene misurata la densità ottica della soluzione standard e la densità ottica della soluzione con il campione. E, poiché si conosce la concentrazione di perossidi contenuta nella soluzione standard pari a 8,9 mgr di H2O2/dl, la concentrazione dei perossidi contenuti nella soluzione campione sarà pari a The optical density of the standard solution and the optical density of the solution with the sample are measured. And, since the peroxide concentration contained in the standard solution is known to be equal to 8.9 mgr of H2O2 / dl, the concentration of peroxides contained in the sample solution will be equal to
C<(perossidi in campione)>= C<(perossidi in sol.standard)>x D<(dens.ottica sol.campione)/>D<(dens.ottica sol.standard)>C <(peroxides in sample)> = C <(peroxides in standard sol)> x D <(optical density in sample sol) /> D <(optic density in standard sol)>
Il Kit per la determinazione della concentrazione di perossido in un liquido organico à ̈ costituito da tre reagenti: The kit for the determination of the peroxide concentration in an organic liquid consists of three reagents:
Reagente A cromogeno di sintesi indiluito N-N Dietil 1,4 phenilendiamina; Reagent A synthesis chromogen undiluted N-N Diethyl 1,4 phenylenediamine;
Reagente B: 136 gr di acetato di sodio e 60 ml di acido acetico in 1.000 ml di acqua distillata; Reagent B: 136 g of sodium acetate and 60 ml of acetic acid in 1,000 ml of distilled water;
Reagente C: H2O2(idroperossido o acqua ossigenata) in acqua distillata alla concentrazione di 8,9 mg di H2O2/dl. Reagent C: H2O2 (hydroperoxide or hydrogen peroxide) in distilled water at a concentration of 8.9 mg of H2O2 / dl.
Il vantaggio del metodo e del Kit secondo la presente invenzione à ̈ di utilizzare un reagente di sintesi indiluito così come viene prodotto, di mescolarne una parte con 1000-6000 parti di una soluzione tampone, reagente B, facilmente preparabile e di ottenere una soluzione di lavoro e, quindi, mescolando 20µl di campione in 1000 µl di soluzione di lavoro, di ottenere la soluzione con il campione. Il passo finale à ̈ di misurare la densità ottica della soluzione standard, reagente C, e della soluzione con il campione, ottenendo la concentrazione di perossidi nel campione di liquido organico sapendo che le due densità ottiche sono proporzionali alle rispettive concentrazioni di perossidi. The advantage of the method and of the Kit according to the present invention is to use an undiluted synthesis reagent as it is produced, to mix a part of it with 1000-6000 parts of an easily prepared buffer solution, reagent B, and to obtain a solution of working and, therefore, mixing 20µl of sample in 1000 µl of working solution, to obtain the solution with the sample. The final step is to measure the optical density of the standard solution, reagent C, and of the solution with the sample, obtaining the peroxide concentration in the organic liquid sample knowing that the two optical densities are proportional to the respective peroxide concentrations.
Il presente metodo à ̈ preciso e consente di determinare in modo semplice la concentrazione di perossidi in qualsiasi liquido organico, non ci sono misurazioni o pesate complicate da eseguire. This method is precise and allows you to easily determine the concentration of peroxides in any organic liquid, there are no complicated measurements or weighings to perform.
Il trovato, bene inteso, non si limita alla rappresentazione data dal modo di realizzazione illustrato ma può ricevere perfezionamenti e modifiche dall'uomo del mestiere senza uscire peraltro dal quadro del brevetto. The invention, well understood, is not limited to the representation given by the embodiment illustrated but can receive improvements and modifications by the man of the art without departing from the framework of the patent.
La presente invenzione consente numerosi vantaggi e di superare difficoltà che non potevano essere vinte con i prodotti attualmente in commercio. The present invention allows numerous advantages and to overcome difficulties that could not be overcome with the products currently on the market.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITCS2008A000020A IT1392880B1 (en) | 2008-11-20 | 2008-11-20 | METHOD AND KIT FOR DETERMINING THE CONCENTRATION OF PEROXIDES IN AN ORGANIC LIQUID |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITCS2008A000020A IT1392880B1 (en) | 2008-11-20 | 2008-11-20 | METHOD AND KIT FOR DETERMINING THE CONCENTRATION OF PEROXIDES IN AN ORGANIC LIQUID |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITCS20080020A1 true ITCS20080020A1 (en) | 2010-05-21 |
| IT1392880B1 IT1392880B1 (en) | 2012-04-02 |
Family
ID=41225737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITCS2008A000020A IT1392880B1 (en) | 2008-11-20 | 2008-11-20 | METHOD AND KIT FOR DETERMINING THE CONCENTRATION OF PEROXIDES IN AN ORGANIC LIQUID |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT1392880B1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862885A (en) * | 1970-11-25 | 1975-01-28 | Ono Pharmaceutical Co | Determination of uric acid in blood with uricase |
| US5246836A (en) * | 1989-08-04 | 1993-09-21 | Kyowa Medex Co., Ltd. | Peroxidase catalyzed enzyme assay by sample prg-treatment |
| US6355489B1 (en) * | 1997-03-21 | 2002-03-12 | Diacron S.R.L. | Method for the determination of oxygen-centered free radicals |
| WO2002099419A1 (en) * | 2001-06-06 | 2002-12-12 | Quest Diagnostics Inc | Composition and method for detecting an adulterant in an aqueous sample |
| US20060134795A1 (en) * | 2004-12-17 | 2006-06-22 | Howarth Jonathan N | Method of analyzing low levels of peroxyacetic acid in water |
-
2008
- 2008-11-20 IT ITCS2008A000020A patent/IT1392880B1/en active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862885A (en) * | 1970-11-25 | 1975-01-28 | Ono Pharmaceutical Co | Determination of uric acid in blood with uricase |
| US5246836A (en) * | 1989-08-04 | 1993-09-21 | Kyowa Medex Co., Ltd. | Peroxidase catalyzed enzyme assay by sample prg-treatment |
| US6355489B1 (en) * | 1997-03-21 | 2002-03-12 | Diacron S.R.L. | Method for the determination of oxygen-centered free radicals |
| WO2002099419A1 (en) * | 2001-06-06 | 2002-12-12 | Quest Diagnostics Inc | Composition and method for detecting an adulterant in an aqueous sample |
| US20060134795A1 (en) * | 2004-12-17 | 2006-06-22 | Howarth Jonathan N | Method of analyzing low levels of peroxyacetic acid in water |
Non-Patent Citations (1)
| Title |
|---|
| BADER H ET AL: "PHOTOMETRIC METHOD FOR THE DETERMINATION OF LOW CONCENTRATIONS OF HYDROGEN PEROXIDE BY THE PEROXIDASE CATALYZED OXIDATION OF N N DIETHYL-P-PHENYLENEDIAMINE DPD", WATER RESEARCH, vol. 22, no. 9, 1988, pages 1109 - 1116, XP002553707 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1392880B1 (en) | 2012-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101813700B (en) | Kit for detecting beta2-microglobulin by nanometer microsphere immunoturbidimetry | |
| Ulker et al. | Mechanical stimulation of nitric oxide synthesizing mechanisms in erythrocytes | |
| CN106018850B (en) | Method and kit for measuring setting time, detecting lupus anticoagulant | |
| von Roten et al. | Molar substitution and C2/C6 ratio of hydroxyethyl starch: influence on blood coagulation | |
| Yang et al. | Silver/Gold Core–Shell Nanoprism‐Based Plasmonic Nanoprobes for Highly Sensitive and Selective Detection of Hydrogen Sulfide | |
| CN101975850A (en) | Diluent for blood cell analyzer | |
| CN103589776A (en) | Small and dense low-density lipoprotein cholesterol determination kit | |
| Liu et al. | Microstructured Optical Fiber-enhanced light–matter Interaction enables highly sensitive exosome-based liquid biopsy of breast Cancer | |
| Altura et al. | Short-term magnesium deficiency results in decreased levels of serum sphingomyelin, lipid peroxidation, and apoptosis in cardiovascular tissues | |
| JP5813878B2 (en) | Method for detecting plasticizers | |
| Kuypers et al. | Unsupervised Machine Learning‐Based Clustering of Nanosized Fluorescent Extracellular Vesicles | |
| Kontovazainitis et al. | Hemostasis in pre-eclamptic women and their offspring: current knowledge and hemostasis assessment with viscoelastic tests | |
| Hertz et al. | Evidence of in vivo exogen protein uptake by red blood cells: a putative therapeutic concept | |
| ITCS20080020A1 (en) | METHOD AND KIT FOR DETERMINING THE CONCENTRATION OF PEROXIDES IN AN ORGANIC LIQUID | |
| Lindahl et al. | Methods for evaluation of platelet function | |
| Schlagenhauf et al. | Polyphosphate in neonates: less shedding from platelets and divergent prothrombotic capacity due to loweR TFPI levels | |
| Wang et al. | PCMT1 gene polymorphisms, maternal folate metabolism, and neural tube defects: a case–control study in a population with relatively low folate intake | |
| CN105548323B (en) | A kind of method of capillary electrophoresis detection concentration of thrombin | |
| ITRM940598A1 (en) | "REACTIVE FOR THE DETERMINATION OF FREE RADICALS" | |
| Ghasemi et al. | Bernard-Soulier syndrome: diagnosis and management | |
| US3511611A (en) | Blood urea nitrogen test | |
| JP2010041951A (en) | Method for detecting target molecule | |
| CN103529020A (en) | Lactic acid measurement kit | |
| CN106967721A (en) | ATP aptamers, method and kit using nanogold color developing detection ATP | |
| Song et al. | Effects of antiplatelet agents on pulmonary haemodynamic response to fMLP in endotoxin primed rats |